XML 95 R71.htm IDEA: XBRL DOCUMENT v3.20.4
Indebtedness - Additional Information (Detail)
1 Months Ended 12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 20, 2023
USD ($)
Sep. 24, 2020
USD ($)
Dec. 13, 2019
USD ($)
Tranch
Nov. 14, 2017
USD ($)
shares
$ / shares
Nov. 30, 2020
Dec. 31, 2020
USD ($)
$ / shares
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Debt Instrument [Line Items]                  
Debt instrument, face amount             $ 1,119,993,000    
Long-term debt             992,493,000 $ 681,900,000  
Convertible Debt, The Term Loan, The Revolver and The Mortgage Loans [Member]                  
Debt Instrument [Line Items]                  
Long-term debt             992,500,000    
Interest expense related to debt facilities             59,900,000 30,700,000 $ 33,700,000
2024 Convertible Notes [Member]                  
Debt Instrument [Line Items]                  
Debt instrument, face amount         $ 570,000,000.0   $ 569,993,000 $ 570,000,000  
Debt instrument, maturity date         Nov. 15, 2024        
Debt instrument, interest rate per annum         1.50%        
Debt instrument, payment frequency             The 2024 Notes contain customary covenants and events of default, occurrence of which permits the certain holders to accelerate all outstanding obligations, including principal and interest.    
Debt instrument, conversion rate         0.013621        
Debt instrument, conversion price | $ / shares         $ 73.42   $ 73.42    
Proceeds for issuance of notes allocated to equity         $ 161,100,000        
Offering costs         4,200,000        
Debt issuance costs         $ 10,600,000        
Effective interest rate percentage             6.90% 6.90% 6.90%
Capped calls strike price | $ / shares         73.42        
Capped calls cap price | $ / shares         104.88        
Amount paid for capped calls transactions         $ 50,900,000        
Debt discount             $ 98,721,000 $ 120,182,000  
Debt issuance costs             6,510,000 $ 7,922,000  
2024 Convertible Notes [Member] | Fundamental Change [Member]                  
Debt Instrument [Line Items]                  
Debt instrument, repurchase price percentage         100.00%        
2024 Convertible Notes [Member] | Minimum [Member] | Beneficial Owner [Member] | Fundamental Change [Member]                  
Debt Instrument [Line Items]                  
Voting percentage         50.00%        
2024 Convertible Notes [Member] | Common Stock [Member]                  
Debt Instrument [Line Items]                  
Debt instrument, convertible into shares | shares         7,763,552        
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | December 2019 Term Loan [Member]                  
Debt Instrument [Line Items]                  
Debt instrument, maturity date     Dec. 31, 2024 Dec. 20, 2023          
Debt instrument, interest rate per annum       8.50%          
Current borrowing capacity       $ 500,000,000.0          
Number of tranches | Tranch       2          
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | December 2019 Term Loan [Member] | Tranch A [Member]                  
Debt Instrument [Line Items]                  
Current borrowing capacity       $ 250,000,000.0          
Line of credit facility, lenders fee       1.75%          
Proceeds after debt discount and issuance cost             244,900,000    
Debt discount             9,400,000    
Debt issuance costs             700,000    
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | December 2019 Term Loan [Member] | Tranch A [Member] | Forecast [Member]                  
Debt Instrument [Line Items]                  
Proceeds after debt discount and issuance cost   $ 5,000,000.0              
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | December 2019 Term Loan [Member] | Tranch B [Member]                  
Debt Instrument [Line Items]                  
Current borrowing capacity     $ 300,000,000.0 $ 250,000,000.0          
Line of credit facility, lenders fee           2.95%      
Prepayment fee percentage       2.00%          
Proceeds after debt discount and issuance cost             291,100,000    
Debt discount             14,900,000    
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | December 2019 Term Loan [Member] | Tranch B [Member] | Forecast [Member]                  
Debt Instrument [Line Items]                  
Proceeds after debt discount and issuance cost $ 6,000,000.0                
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | Minimum [Member] | December 2019 Term Loan [Member]                  
Debt Instrument [Line Items]                  
Prepayment fee percentage       1.00%          
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | Maximum [Member] | December 2019 Term Loan [Member]                  
Debt Instrument [Line Items]                  
Prepayment fee percentage       2.00%          
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | Maximum [Member] | December 2019 Term Loan [Member] | Tranch B [Member]                  
Debt Instrument [Line Items]                  
Debt issuance costs             $ 100,000